Strong predictive value of mannose-binding lectin levels for cardiovascular risk of hemodialysis patients

Journal of Translational Medicine

Volumn 14, Issue 1, 2016, Pages

  Poppelaars, Felix ^a   Gaya da Costa, Mariana ^a   Berger, Stefan P ^a   Assa, Solmaz ^a   Meter Arkema, Anita H ^a   Daha, Mohamed R ^a,b   Son, Willem J ^a   Franssen, Casper F M ^a   Seelen, Marc A J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular; Complement; Hemodialysis; MBL; Risk

Indexed keywords

COMPLEMENT COMPONENT C3D; COMPLEMENT MEMBRANE ATTACK COMPLEX; MANNOSE BINDING LECTIN; PROPERDIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CONGESTIVE HEART FAILURE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; SUDDEN CARDIAC DEATH; TRANSLUMINAL CORONARY ANGIOPLASTY; ADVERSE EFFECTS; BLOOD; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; RISK FACTOR;

CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMPLEMENT C3D; COMPLEMENT MEMBRANE ATTACK COMPLEX; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MANNOSE-BINDING LECTIN; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPERDIN; RENAL DIALYSIS; RISK FACTORS;

EID: 84983507492     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-016-0995-5     Document Type: Article

References (48)

1. Yoshino M, Kuhlmann MK, Kotanko P, Greenwood RN, Pisoni RL, Port FK, et al. International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality. J Am Soc Nephrol. 2006;17:3510-9.
2. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15:1307-15.
3. Chien C-C, Yen C-S, Wang J-J, Chen H-A, Chou M-T, Chu C-C, et al. Reverse epidemiology of hypertension-mortality associations in hemodialysis patients: a long-term population-based study. Am J Hypertens. 2012;25:900-6.
4. Swaminathan S, Shah SV. Novel inflammatory mechanisms of accelerated atherosclerosis in kidney disease. Kidney Int. 2011;80:453-63.
5. Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344:1058-66.
6. Takahashi K, Ip WE, Michelow IC, Ezekowitz RAB. The mannose-binding lectin: a prototypic pattern recognition molecule. Curr Opin Immunol. 2006;18:16-23.
7. Petersen SV, Thiel S, Jensenius JC. The mannan-binding lectin pathway of complement activation: biology and disease association. Mol Immunol. 2001;38:133-49.
8. Garred P, Honoré C, Ma YJ, Munthe-Fog L, Hummelshøj T. MBL2, FCN1, FCN2 and FCN3-The genes behind the initiation of the lectin pathway of complement. Mol Immunol. 2009;46:2737-44.
9. Dean MM, Minchinton RM, Heatley S, Eisen DP. Mannose binding lectin acute phase activity in patients with severe infection. J Clin Immunol. 2005;25:346-52.
10. Pagowska-Klimek I, Cedzýski M. Mannan-binding lectin in cardiovascular disease. Biomed Res Int. 2014;2014:616817.
11. Keller TT. Serum levels of mannose-binding lectin and the risk of future coronary artery disease in apparently healthy men and women. Arterioscler Thromb Vasc Biol. 2006;26:2345-50.
12. Saevarsdottir S, Oskarsson OO, Aspelund T, Eiriksdottir G, Vikingsdottir T, Gudnason V, et al. Mannan binding lectin as an adjunct to risk assessment for myocardial infarction in individuals with enhanced risk. J Exp Med. 2005;201:117-25.
13. Vengen IT, Madsen HO, Garred P, Platou C, Vatten L, Videm V. Mannose-binding lectin deficiency is associated with myocardial infarction: the HUNT2 study in Norway. PLoS ONE. 2012;7:e42113.
14. Matthijsen RA, de Winther MPJ, Kuipers D, van der Made I, Weber C, Herias MV, et al. Macrophage-specific expression of mannose-binding lectin controls atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. 2009;119:2188-95.
15. Alipour A, van Oostrom AJHHM, Van Wijk JPH, Verseyden C, Plokker HWM, Jukema JW, et al. Mannose binding lectin deficiency and triglyceride-rich lipoprotein metabolism in normolipidemic subjects. Atherosclerosis. 2009;206:444-50.
16. Fraser DA, Tenner AJ. Innate immune proteins C1q and mannan-binding lectin enhance clearance of atherogenic lipoproteins by human monocytes and macrophages. J Immunol. 2010;185:3932-9.
17. Satomura A, Fujita T, Yanai M, Kumasaka K, Uehara Y, Okada K, et al. Functional mannose-binding lectin levels in patients with end-stage renal disease on maintenance hemodialysis. J Innate Immun. 2012;4:293-300.
18. Mares J, Richtrova P, Hricinova A, Tuma Z, Moravec J, Lysak D, et al. Proteomic profiling of blood-dialyzer interactome reveals involvement of lectin complement pathway in hemodialysis-induced inflammatory response. Proteomics Clin Appl. 2010;4:829-38.
19. Damman J, Seelen MA. Mannan binding lectin: a two-faced regulator of renal allograft injury? Kidney Int. 2013;83:191-3.
20. Garred P, Larsen F, Madsen HO, Koch C. Mannose-binding lectin deficiency-revisited. Mol Immunol. 2003;40:73-84.
21. Garred P, Larsen F, Seyfarth J, Fujita R, Madsen HO. Mannose-binding lectin and its genetic variants. Genes Immun. 2006;7:85-94.
22. Assa S, Hummel YM, Voors AA, Kuipers J, Westerhuis R, de Jong PE, et al. Hemodialysis-induced regional left ventricular systolic dysfunction: prevalence, patient and dialysis treatment-related factors, and prognostic significance. Clin J Am Soc Nephrol. 2012;7:1615-23.
23. Flythe JE, Kimmel SE, Brunelli SM. Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality. Kidney Int. 2011;79:250-7.
24. Damman J, Seelen MA, Moers C, Daha MR, Rahmel A, Leuvenink HG, et al. Systemic complement activation in deceased donors is associated with acute rejection after renal transplantation in the recipient. Transplantation. 2011;92:163-9.
25. Berger SP, Roos A, Mallat MJK, Fujita T, De Fijter JW, Daha MR. Association between mannose-binding lectin levels and graft survival in kidney transplantation. Am J Transplant. 2005;5:1361-6.
26. Fijen CA, van den Bogaard R, Daha MR, Dankert J, Mannens M, Kuijper EJ. Carrier detection by microsatellite haplotyping in 10 properdin type 1-deficient families. Eur J Clin Invest. 1996;26:902-6.
27. Peakman M, Lobo-Yeo A, Senaldi G, Nilsson M, Tee DEH, Vergani D. Quantification of C3d in biological fluids by an enzyme-linked immunosorbent assay. J Immunol Methods. 1987;104:51-6.
28. Fijen CA, Kuijper EJ, Te Bulte M, van de Heuvel MM, Holdrinet AC, Sim RB, et al. Heterozygous and homozygous factor H deficiency states in a Dutch family. Clin Exp Immunol. 1996;105:511-6.
29. Austin PC, Steyerberg EW, Steyerberg E, Steyerberg E, Vickers A, Cook N, et al. Interpreting the concordance statistic of a logistic regression model: relation to the variance and odds ratio of a continuous explanatory variable. BMC Med Res Methodol. 2012;12:82.
30. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21:128-38.
31. Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157-72 (discussion 207-12).
32. Berger SP, Roos A, Mallat MJK, Schaapherder AFM, Doxiadis II, van Kooten C, et al. Low pretransplantation mannose-binding lectin levels predict superior patient and graft survival after simultaneous pancreas-kidney transplantation. J Am Soc Nephrol. 2007;18:2416-22.
33. Roos A, Garred P, Wildenberg M, Lynch N, Munoz J, Zuiverloon T, et al. Antibody-mediated activation of the classical pathway of complement may compensate for mannose-binding lectin deficiency. Eur J Immunol. 2004;9:2589-98.
34. Siezenga MA, Chandie Shaw PK, Daha MR, Rabelink TJ, Berger SP. Low mannose-binding lectin (MBL) genotype is associated with future cardiovascular events in type 2 diabetic south asians a prospective cohort study. Cardiovasc Diabetol. 2011;10:60.
35. Troelsen LN, Garred P, Jacobsen S. Mortality and predictors of mortality in rheumatoid arthritis-a role for mannose-binding lectin? J Rheumatol. 2010;37:536-43.
36. Kotimaa J, Klar-Mohamad N, Schilders G, Rutjes H, Daha MR, van Kooten C. Sex matters: systemic complement activity of female C57bl/6 mice is limited by serum terminal pathway components. Mol Immunol. 2015;76:13-21.
37. Kildey K, Rooks K, Weier S, Flower RL, Dean MM. Effect of age, gender and mannose-binding lectin (MBL) status on the inflammatory profile in peripheral blood plasma of Australian blood donors. Hum Immunol. 2014;75:973-9.
38. Ip WK, To YF, Cheng SK, Lau YL. Serum mannose-binding lectin levels and mbl2 gene polymorphisms in different age and gender groups of southern Chinese adults. Scand J Immunol. 2004;59:310-4.
39. Shushimita S, Van Der Pol P, De Bruin RWF, Ijzermans JNM, Van Kooten C, Dor FJMF. Mannan-binding lectin is involved in the protection against renal ischemia/reperfusion injury by dietary restriction. PLoS ONE. 2015;10:1-14.
40. Ishii M, Ohsawa I, Inoshita H, Kusaba G, Onda K, Wakabayashi M, et al. Serum concentration of complement components of the lectin pathway in maintenance hemodialysis patients, and relatively higher levels of L-Ficolin and MASP-2 in Mannose-binding lectin deficiency. Ther Apher Dial. 2011;15:441-7.
41. Satomura A, Fujita T, Fuke Y, Yanai M, Kumasaka K, Takayama E, et al. Relationship between oligomer and functional serum mannose-binding lectin in chronic renal failure. Eur J Clin Invest. 2010;40:865-73.
42. Satomura A, Endo M, Fujita T, Ohi H, Ohsawa I, Fuke Y, et al. Serum mannose-binding lectin levels in maintenance hemodialysis patients: impact on all-cause mortality. Nephron Clin Pract. 2006;102:c93-9.
43. Lines SW, Richardson VR, Thomas B, Dunn EJ, Wright MJ, Carter AM. Complement and cardiovascular disease-the missing link in haemodialysis patients. Nephron. 2016;132:5-14.
44. Genster N, Takahashi M, Sekine H, Endo Y, Garred P, Fujita T. Lessons learned from mice deficient in lectin complement pathway molecules. Mol Immunol. 2014;61:59-68.
45. Pavlov VI, Tan YS, McClure EE, La Bonte LR, Zou C, Gorsuch WB, et al. Human mannose-binding lectin inhibitor prevents myocardial injury and arterial thrombogenesis in a novel animal model. Am J Pathol. 2015;185:347-55.
46. Madsen HO, Videm V, Svejgaard A, Svennevig JL, Garred P. Association of mannose-binding-lectin deficiency with severe atherosclerosis. Lancet (London, England). 1998;352:959-60.
47. Hegele RA, Ban MR, Anderson CM, Spence JD. Infection-susceptibility alleles of mannose-binding lectin are associated with increased carotid plaque area. J Investig Med. 2000;48:198-202.
48. Hornum M, Bay JT, Clausen P, Melchior Hansen J, Mathiesen ER, Feldt-Rasmussen B, et al. High levels of mannose-binding lectin are associated with lower pulse wave velocity in uraemic patients. BMC Nephrol. 2014;15:162. doi: 10.1186/1471-2369-15-162.